Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine

Haematologica

Volumn 97, Issue 12, 2012, Pages 1929-1931

  Gavillet, Mathilde ^a   Noetzli, Jasmine ^a   Blum, Sabine ^a   Duchosal, Michel A ^a   Spertini, Olivier ^a   Lambert, Jean Francois ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

5 azacytidine; Acute myeloid leukemia; Survival; Transfusion independence

Indexed keywords

AZACITIDINE; CYTARABINE; DNA METHYLTRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; ERYTHROCYTE TRANSFUSION; HUMAN; LETTER; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZACITIDINE; BLOOD TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84870427766     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.065151     Document Type: Letter

References (12)

1. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895-903.
2. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, et al. Prognostic factors for response and overall survivalin 282 patients with higher-risk myelodysplastic syndromes treatedwith azacitidine. Blood. 2011;117(2):403-11.
3. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyureawith or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114-24.
4. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise PY, TertianG, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990;8(2):272-9.
5. Silverman LR. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenancetherapy, effects on transfusion and combination with otheragents. Leuk Res. 2009;33 (Suppl 2):S18-21.
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival comparedwith conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol.2010;28(4):562-9.
7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that ofconventional care regimens in the treatment of higher-riskmyelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
8. Lyons RM, Cosgriff T, Modi S, McIntyre H, Beach CL, BackstromJT. Tolerability and hematologic improvement assessed using threealternative dosing schedules of azacitidine in patients withmyelodysplastic syndromes. ASCO Meeting Abstracts. 2007; 25:7083.
9. Gore SD. New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome. ASH Education Program Book. 2011;2011:550-5.
10. Cornelissen JJ, van Putten WLJ, Verdonck LF, Theobald M, Jacky E, Daenen SMG, et al. Results of a HOVON/SAKK donor versus nodonor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in youngand middle-aged adults: benefits for whom? Blood. 2007;109(9):3658-66.
11. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-9.
12. Seymour JF, Santini V, Fenaux P, Giagounidis AAN, Sanz GF, Finelli C, et al. Achievement of Red Blood Cell (RBC) TransfusionIndependence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs. ASH Annual Meeting Abstracts. 2010;116:1856.